BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Oncology

Health Canada Approves Illuccix® for Prostate Cancer Imaging

Illuccix™ [kit for the preparation of gallium (68Ga) gozetotide injection], after radiolabeling with gallium (68Ga), is indicated for use with the po...

October 14, 2022 | News

First patient treated in Clarity's therapeutic prostate cancer trial

Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT0...

October 10, 2022 | News

China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers

Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality med...

October 10, 2022 | News

First Patient in New Zealand Dosed with Illuccix® - Telix's Prostate Cancer Imaging Agent

As Illuccix rolls out to positron emission tomography (PET) sites across the country, Mercy Radiology in Auckland became the first to administer ...

September 30, 2022 | News

Australia approved New treatment for rare cancer cholangiocarcinoma

A NEW targeted therapy to treat a rare bile duct cancer called cholangiocarcinoma has been approved for use in Australia. PEMAZYRE® (pemigat...

September 16, 2022 | News

Merck announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in patients

First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative potential...

September 14, 2022 | News

SeekIn Receives CE Mark Approval for OncoSeek® Multi-Cancer Detection Test

SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark approva...

September 13, 2022 | News

Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive early data for two novel and investigational bispecific antibodies – uba...

September 12, 2022 | News

Merck to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients

Late-breaking data highlight 5-year survival results from Phase II study of the investigational IAP inhibitor xevinapant in the curative setting of unres...

September 08, 2022 | News

Zhongchao Inc. Announces its New Strategy Extension Focusing on the Oncology and Other Major Disease Management

Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare inform...

September 02, 2022 | News

Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA)

lacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line...

August 21, 2022 | News

Sirnaomics Commence Treatment of Facial Squamous Cell Skin Cancer In Situ

Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi t...

August 19, 2022 | News

Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China

Collaboration to accelerate the development and access of oncology medicines for cancer patients in China Clinical trial programs combining two of ...

August 05, 2022 | News

BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology

Research team ‘EDC’ will study ‘Extrachromosomal DNA in Cancer’. With this project, the two partners launch their ninth collabor...

August 02, 2022 | News

Stay Connected